Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
3
Neutral
8
Bullish
3
Bearish
35
Neutral
8
Bullish
3
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Bearish
32
Neutral
0
Bullish
0
Jubilant Pharmova is an integrated global pharmaceutical company operating six businesses — Radiopharma (manufacturing and 45 radiopharmacies in the US), Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (drug discovery and API CDMO), Generics and Proprietary Novel Drugs — focused on specialty products and onshore manufacturing for the US market.
Q1'FY27 revenue was Rs. 2,229 crore, up 17% YoY, but EBITDA fell to Rs. 268 crore (11.9% margin) due to temporary unavailability of high-margin SPECT products and higher operating and remediation costs at the Montreal CMO; management expects margins to recover from H2'FY27 as SPECT supply normalises.
The company is executing material capacity expansion: expanding PET manufacturing from 3 to 9 US sites (USD 60+ million), installing Lines 3 and 4 at Spokane and Line 5 isolator at Montreal (USD 114 million), aiming to more than double revenues by FY30 under its Vision 2030 plan and capture onshore CDMO demand driven by tariffs and supply‑chain reshoring.
Jubilant Pharmova combines product innovation (Ruby-Fill® cardiac PET with AI-enabled 3D quantification) with a growing proprietary pipeline (JBI-802, JBI-778) and strategic partnerships (Pierre Fabre, PET manufacturers), positioning the company to monetise diagnostics, therapeutic radiopharma, CDMO tech transfers and novel drug assets over the medium term.
Pharmaceuticals & Biotechnology
Pharmaceuticals
14,764 Cr
Low Risk
42.0
37.0
0.8
2.1
1,183.90
783.75
Sales CAGR
Profit CAGR
ROE
ROCE
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Jubilant Pharmova Ltd (JUBLPHARMA) is currently trading at 926.80 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Jubilant Pharmova is an integrated global pharmaceutical company operating six businesses — Radiopharma (manufacturing and 45 radiopharmacies in the US), Allergy Immunotherapy, CDMO Sterile Injectables, CRDMO (drug discovery and API CDMO), Generics and Proprietary Novel Drugs — focused on specialty products and onshore manufacturing for the US market. Q1'FY27 revenue was Rs. 2,229 crore, up 17% YoY, but EBITDA fell to Rs. 268 crore (11.9% margin) due to temporary unavailability of high-margin SPECT products and higher operating and remediation costs at the Montreal CMO; management expects margins to recover from H2'FY27 as SPECT supply normalises. The company is executing material capacity expansion: expanding PET manufacturing from 3 to 9 US sites (USD 60+ million), installing Lines 3 and 4 at Spokane and Line 5 isolator at Montreal (USD 114 million), aiming to more than double revenues by FY30 under its Vision 2030 plan and capture onshore CDMO demand driven by tariffs and supply‑chain reshoring. Jubilant Pharmova combines product innovation (Ruby-Fill® cardiac PET with AI-enabled 3D quantification) with a growing proprietary pipeline (JBI-802, JBI-778) and strategic partnerships (Pierre Fabre, PET manufacturers), positioning the company to monetise diagnostics, therapeutic radiopharma, CDMO tech transfers and novel drug assets over the medium term.
Over the past 52 weeks, Jubilant Pharmova Ltd has traded between a low of ₹783.75 and a high of ₹1,183.90. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Jubilant Pharmova Ltd has a market capitalization of approximately 15,012.43. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Jubilant Pharmova Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 42.72 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 15,012.43 Cr, Jubilant Pharmova Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Jubilant Pharmova Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Jubilant Pharmova Ltd is 42.72. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Jubilant Pharmova said its subsidiary Jubilant Generics received tentative USFDA approval for Pantoprazole Sodium Delayed Release Oral Suspension, 40 mg per packet.
The USFDA concluded an inspection on June 17, 2026 and issued eight observations, according to Jubilant Pharmova’s disclosure.
They cited near-term impact risks from remediation or shutdown at the Montreal facility in Canada, SPECT product supply shortages, and higher depreciation.
Reports cited a consolidated net profit of ₹151.3 crore in Q4 FY25, while another market report pegged it at ₹153.60 crore, versus a loss in Q4 FY24.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1150.00 | 16,145 Cr | 22.47 | 3.90 | 0.62 | 17.07 | 12.58 | 9.48 | ||
6383.20 | 15,745 Cr | 92.83 | 18.04 | 0.57 | 21.49 | 25.53 | 8.53 | ||
797.80 | 15,630 Cr | 22.67 | 2.75 | 1.51 | 11.89 | 10.81 | 7.87 | ||
782.50 | 15,453 Cr | 15.24 | 1.47 | 0.58 | 15.38 | 15.37 | 9.16 | ||
926.80 | 15,012 Cr | 42.72 | 2.12 | 0.53 | 5.62 | 6.41 | 2.26 | ||
306.25 | 14,279 Cr | 27.39 | 4.72 | 0.29 | 13.82 | 17.37 | 13.50 | ||
2166.90 | 13,547 Cr | 68.07 | 18.14 | 0.45 | 24.79 | 27.13 | 16.52 | ||
| Median: 7 Co. | — | 926.80 | 15,453 Cr | 27.39 | 3.90 | 0.57 | 15.38 | 15.37 | 9.16 |
